Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study
Standard
Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. / Tregouet, D A; Schnabel, R; Alessi, M C; Godefroy, T; Declerck, P J; Nicaud, V; Munzel, T; Bickel, C; Rupprecht, H J; Lubos, E; Zeller, T; Juhan-Vague, I; Blankenberg, S; Tiret, L; Morange, P E; AtheroGene Investigators.
in: J THROMB HAEMOST, Jahrgang 7, Nr. 1, 01.2009, S. 49-57.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study
AU - Tregouet, D A
AU - Schnabel, R
AU - Alessi, M C
AU - Godefroy, T
AU - Declerck, P J
AU - Nicaud, V
AU - Munzel, T
AU - Bickel, C
AU - Rupprecht, H J
AU - Lubos, E
AU - Zeller, T
AU - Juhan-Vague, I
AU - Blankenberg, S
AU - Tiret, L
AU - Morange, P E
AU - AtheroGene Investigators
PY - 2009/1
Y1 - 2009/1
N2 - BACKGROUND: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent.OBJECTIVES: We investigated the association between TAFI levels and the risk of cardiovascular events in CAD.PATIENTS/METHODS: 1668 individuals with angiographically proven CAD at baseline were followed for a median of 2.3 years, as part of the prospective AtheroGene cohort. Fifty-six deaths from cardiovascular (CV) causes and 35 non-fatal CV events were observed.RESULTS: At baseline, three TAFI measurements were available: one evaluating the total amount of TAFI (t-TAFI), one measuring the TAFIa/TAFIai amount, and the last the released activated peptide (TAFI-AP). TAFIa/TAFIai levels were associated with increased risk of CV death [hazard ratio (HR) for one tertile increase, 2.38 (1.56-3.63); P < 10(-4)]. This association remained significant after adjustment for conventional risk factors, CRP levels, white blood count and markers of thrombin generation and fibrinolysis [HR = 1.69 (1.07-2.67); P = 0.01]. In addition, CPB2 gene polymorphisms explained 12%, 6%, and 3% of t-TAFI, TAFIa/TAFIai and TAFI-AP levels, respectively, but none was associated with CV events.CONCLUSIONS: The amount of activated TAFI, measured by TAFIa/TAFIai ELISA, but not of the t-TAFI is independently associated with the risk of CV death.
AB - BACKGROUND: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent.OBJECTIVES: We investigated the association between TAFI levels and the risk of cardiovascular events in CAD.PATIENTS/METHODS: 1668 individuals with angiographically proven CAD at baseline were followed for a median of 2.3 years, as part of the prospective AtheroGene cohort. Fifty-six deaths from cardiovascular (CV) causes and 35 non-fatal CV events were observed.RESULTS: At baseline, three TAFI measurements were available: one evaluating the total amount of TAFI (t-TAFI), one measuring the TAFIa/TAFIai amount, and the last the released activated peptide (TAFI-AP). TAFIa/TAFIai levels were associated with increased risk of CV death [hazard ratio (HR) for one tertile increase, 2.38 (1.56-3.63); P < 10(-4)]. This association remained significant after adjustment for conventional risk factors, CRP levels, white blood count and markers of thrombin generation and fibrinolysis [HR = 1.69 (1.07-2.67); P = 0.01]. In addition, CPB2 gene polymorphisms explained 12%, 6%, and 3% of t-TAFI, TAFIa/TAFIai and TAFI-AP levels, respectively, but none was associated with CV events.CONCLUSIONS: The amount of activated TAFI, measured by TAFIa/TAFIai ELISA, but not of the t-TAFI is independently associated with the risk of CV death.
KW - Aged
KW - Carboxypeptidase B/genetics
KW - Carboxypeptidase B2/blood
KW - Coronary Artery Disease/blood
KW - Death, Sudden, Cardiac
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Proportional Hazards Models
KW - Risk
KW - Risk Factors
U2 - 10.1111/j.1538-7836.2008.03221.x
DO - 10.1111/j.1538-7836.2008.03221.x
M3 - SCORING: Journal article
C2 - 19017260
VL - 7
SP - 49
EP - 57
JO - J THROMB HAEMOST
JF - J THROMB HAEMOST
SN - 1538-7933
IS - 1
ER -